SEOUL, South Korea, Oct. 24, 2025 /PRNewswire/ — Sendbird, the leading communication platform for modern apps, today announced its AI Agent System has earned ISO/IEC 42001 certification, the world’s first international standard for Artificial Intelligence Management Systems (AIMS). This achievement underscores Sendbird’s commitment to developing and deploying AI responsibly—embedding governance, transparency and risk-management into every stage of its AI agent lifecycle.

The ISO/IEC 42001 standard provides a comprehensive framework for ethical and accountable AI practices. By attaining certification, Sendbird validates that its AI systems meet stringent global requirements for managing risks related to bias, fairness, privacy and security.

“Earning ISO 42001 certification reinforces our promise to build AI products that are safe, transparent and trustworthy,” said John S. Kim, CEO of Sendbird. “Responsible AI has always been integral to our innovation, and this recognition affirms our commitment to operational excellence and governance at scale.”

This milestone builds upon Sendbird’s internal Trust OS framework—a foundation designed to ensure consistent AI governance through structured policies, continuous model monitoring, and full visibility into decision-making processes. By aligning Trust OS with the ISO/IEC 42001 framework, Sendbird ensures its AI agents are tested, evaluated, and refined to meet enterprise-grade standards of security, compliance, and accountability.

By meeting this standard, Sendbird demonstrates that responsible AI is more than a principle—it’s a practice embedded across development, deployment and lifecycle operations. The company maintains rigorous oversight, actively manages AI risks and stays ahead of emerging global compliance requirements.

“This certification is not the finish line—it’s the beginning of a new standard for responsible AI,” Kim added. “We’ll continue to set the benchmark for transparency and trust as AI becomes essential to every digital experience. As one of the early movers in operationalizing responsible AI at scale, we’re proud to help define what trustworthy AI means in practice.”

About Sendbird

Sendbird is the leading omnichannel AI-agent and communications platform that empowers global enterprises to deliver seamless, personalized customer experiences through chat, voice, video and business messaging. Trusted by thousands of brands, Sendbird powers billions of conversations each month with enterprise-grade reliability, security and compliance. Headquartered in California, with offices in Seoul and San Mateo, Sendbird is backed by ICONIQ, SoftBank, Tiger Global, Y Combinator and other leading investors.

FACO 2025 presentation highlights HCB101’s favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers.

TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies, today presented new results from its ongoing Phase 1 study of HCB101, a novel SIRPα-engineered Fc fusion protein, at the 13^th International Conference of the Federation of Asian Clinical Oncology (FACO 2025), held October 24-25, 2025, in Shanghai, Mainland China.

Dr. Fangling Ning, an investigator at the Affiliated Hospital of Binzhou Medical University, stated, “HCB101 is showing early promise as a differentiated therapy targeting the CD47-SIRPα axis, with encouraging signals of efficacy in both solid tumors and lymphomas. Importantly, the novel design (engineered with the help of AI) effectively mitigated anemia and cytopenias, which have been challenges with prior agents in this class. These findings provide a strong foundation for further clinical development.”

The poster, titled “Phase 1 Study of HCB101, a Novel Fc-engineered CD47-SIRPα Fusion Protein, Demonstrates Favorable Safety and Confirmed Responses in Solid and Hematologic Malignancies“, reported updated results from the multinational, first-in-human trial (NCT05892718). Key highlights from the study as of July 10, 2025, include:

• Favorable safety profile: Among 49 patients enrolled across 10 dose levels (0.08-18.00 mg/kg, QW), only one dose-limiting toxicity (DLT) was observed, a transient Grade 3 thrombocytopenia at the 2.56 mg/kg dose level.
• Consistent receptor occupancy (RO): >90% CD47 RO achieved at doses ≥1.28 mg/kg.
• Encouraging antitumor activity: Two confirmed partial responses (PRs) in head and neck squamous cell carcinoma (HNSCC) and non-Hodgkin lymphoma, alongside durable disease control in multiple patients.

“The presentation of HCB101 data at FACO 2025 underscores both the scientific innovation of our FBDB™ platform and our commitment to developing next-generation immunotherapies with global impact,” said Scott Liu, Ph.D., Chairman, CEO, and Founder of HanchorBio. “We are encouraged by the excellent safety profile and initial responses observed in heavily pretreated patients. These monotherapy data establish safety, PK/PD, and early activity, providing the foundation for our ongoing combination trials testing HCB101 layered onto standard backbones in multiple tumor types. This marks an important step toward realizing our vision of bringing transformative, differentiated treatments to patients facing cancers with high unmet need.”

About HCB101: A Differentiated CD47-SIRPα Blockade
HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio’s proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood cell (RBC) binding, thereby avoiding the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging. Key differentiators of HCB101:

• Enhanced safety: Cytopenia-sparing profile, with no DLTs observed up to 24 mg/kg and >90% RO at ≥1.28 mg/kg, supporting a broad therapeutic window.
• Robust immune activation: Engineered to enhance ADCP and bridge innate-to-adaptive immunity, with evidence of durable immune-mediated tumor control in monotherapy.
• Broad tumor applicability: Demonstrated activity across >80 PDX and CDX preclinical models, with early clinical signals in gastric cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, non-Hodgkin lymphoma, and ovarian cancer.
• Clinical translation: Shows durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in second-line gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in first-line TNBC and second-line HNSCC, substantially exceeding historical benchmarks.

About HCB101 Monotherapy Clinical Trial (HCB101-101; NCT05892718)
HCB101-101 is an ongoing multi-national, multi-center, open-label, dose-finding Phase 1 study evaluating HCB101 in adults with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma. Conducted across sites in Taiwan, the United States, and Mainland China, the study uses a stepwise accelerated flat-dosing adjustment strategy to optimize safety and dosing. The primary objectives are to assess safety and tolerability, while secondary endpoints include pharmacokinetics, pharmacodynamics, and antitumor activity. Early data demonstrate a favorable safety profile, dose-proportional pharmacokinetics, high-level CD47 receptor occupancy, and confirmed partial responses in heavily pretreated solid tumor and lymphoma patients. These findings support the continued development of HCB101 in expansion cohorts and future combination studies.

About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and global development, aiming to rewrite cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: www.HanchorBio.com

In the news release, World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis, issued 23-Oct-2025 by IFPA over PR Newswire, we are advised by the company that the quotation by Frida Dunger, Executive Director of IFPA, should read “It’s also time to move towards increased understanding that psoriasis is not just a skin disease,” rather than “It’s also time to move towards increased understanding that psoriasis is just a skin disease,” as originally issued inadvertently. The complete, corrected release follows:

World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis

IFPA urges recognition of the close link between psoriasis and mental health — and action to prevent its devastating ripple effects.

STOCKHOLM, Oct. 24, 2025 /PRNewswire/ — Every year on October 29, the global community marks World Psoriasis Day, raising awareness and standing in solidarity with more than 60 million people living with psoriatic disease worldwide. This year, IFPA (the International Federation of Psoriasis Associations) launches a global campaign “Stop the Domino Effect”.

World Psoriasis Day 2025 – campaign main theme

IFPA’s “Stop the Domino Effect” is urging policymakers, healthcare professionals and the public to recognize psoriasis for what it is: a serious, systemic, and life-changing disease that sets off a chain reaction of serious health conditions — from diabetes and cardiovascular disease to depression. The campaign highlights the urgent need for integrated care, early intervention and equal access to treatment worldwide. The organization calls on health authorities to include psoriasis in national NCD strategies and ensure that patients receive care addressing both physical and mental health.

Psoriasis is not “just a skin disease” as it has been misunderstood for a long time. It is a lifelong, immune-mediated condition that affects the entire body. The body’s immune system triggers an overproduction of skin cells, leading to painful, inflamed, and itchy plaques. But the damage goes far deeper than the surface.

Recent research shows that psoriasis is closely linked to other noncommunicable diseases (NCDs) such as obesity, diabetes, cardiovascular disease, and metabolic syndrome. One in three people with psoriasis will develop psoriatic arthritis, a painful inflammatory joint disease that can cause permanent damage and disability.

The burden extends to mental health. People with psoriasis are more than twice as likely to experience serious psychological distress — with a 109% higher risk of developing mental health disorders compared to the general population. One in ten live with diagnosed depression, while nearly half report severe anxiety. The stigma is pervasive: four in five people say they have faced discrimination because of their disease, and one in three have had to give up educational or career opportunities as a result.

• “We must stop the domino effect of psoriatic disease — and we must do it now,” says **Frida Dunger, Executive Director of IFPA. ” *It’s time to recognize that psoriatic disease severely affects every part of a person’s life and is closely linked to mental health. It’s also time to move towards increased understanding that psoriasis is not just a skin disease. If we treat psoriasis early, with the best possible treatment and in holistic way, we can prevent a cascade of other serious illnesses. Policymakers and healthcare providers must act with urgency and listen to those living with the condition. Stopping the domino effect of psoriasis can help to radically improve lives of many people and save them from preventable suffering, – *Frida added.

This World Psoriasis Day, IFPA reminds the world: it’s time to stop the domino effect.

Read more about this year’s campaign: 
https://www.ifpa-pso.com/global-actions-overview/world-psoriasis-day

About IFPA 
IFPA (the International Federation of Psoriasis Associations), founded in 1971 and based in Stockholm, Sweden, is the global organization dedicated to advocating for everyone affected by psoriatic disease. IFPA’s members include national and regional patient associations and represent over 60 million people worldwide. Through global coalitions, World Psoriasis Day campaigns, the IFPA Forum, and the World Psoriasis & Psoriatic Arthritis Conference, IFPA is redefining psoriatic disease as a key lens for stronger, more inclusive health systems. Learn more: https://www.ifpa-pso.com/

LONDON, Oct. 24, 2025 /PRNewswire/ — Geely Auto today officially launched the Geely EX5, an award-winning all-electric SUV, in the United Kingdom. This launch reinforces Geely Auto’s commitment to sustainable mobility and its ambition to become a leading force in the European market.

Geely Auto has set ambitious goals for the UK market, targeting annual sales of 100,000 vehicles by 2030. This growth will be supported by a nationwide network of 100 sales and service outlets by 2026, complemented by a robust parts distribution and maintenance system – ensuring exceptional service for every owner across the country.

Jerry Gan, CEO of Geely Auto Group, stated, “Entering the UK market marks a significant milestone in deepening Geely’s European strategy and heralds a new chapter in electric mobility across Europe. We are committed to delivering innovative and sustainable products while building enduring relationships of mutual trust with our customers and partners. Geely Auto looks forward to advancing alongside the European market and co-creating the future.”

Before entering the UK market, Geely Auto had already established a presence in 12 European countries, including Poland, Greece, and Croatia. Backed by world-class R&D centers across Europe and Asia and a strong business footprint, Geely Auto will continue to advance into key markets such as Italy, Germany, France, and Spain etc. Over the next five years, Geely Auto is scheduled to launch 15 new vehicles tailored for European consumers, aiming to establish itself as a mainstream automotive brand in Europe, supported by a network of over 1,000 sales outlets.

The Geely EX5’s UK debut builds on impressive global momentum, with its availability in 33 countries and remarkable success across diverse markets. For example, Australia has embraced the model with exceptional enthusiasm, achieving rapid growth since its launch in March 2025. In Brazil, the EX5 dominated its segment, securing the number one sales position for two consecutive months following its official launch.

Geely Auto’s parent company, Geely Holding Group, has maintained deep roots in the UK for nearly two decades. The company’s presence began in 2006 with an investment and partnership with the London Taxi Company, which later became LEVC under Geely’s ownership, and still produces the award-winning and zero-emission taxi vehicle. Since then, Geely Holding has expanded its footprint through strategic investment in iconic British brands such as Lotus and Aston Martin, driving innovation in electrification and luxury mobility.

SINGAPORE, Oct. 24, 2025 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), today announced that it has received a notification letter (the “Notification Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) dated October 21, 2025, notifying the Company the closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share.

This announcement is being made in accordance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon receipt of a deficiency notification. The receipt of the Notification Letter has no immediate impact on the Company’s business operations or the listing of its Class A Shares, which will continue to trade uninterrupted on Nasdaq under the ticker symbol “YYGH.”

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until April 20, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s Class A Shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive trading days. If the Company does not regain compliance by April 20, 2026, the Company may be eligible for additional time, assuming the absence of other deficiencies.

The Company will continue to monitor its closing bid price and assess all available options to restore compliance through appropriate corporate measures. YY Group remains committed to advancing its strategic initiatives, strengthening financial performance, and creating sustainable long-term value for shareholders.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, forecasts, and projections about the operating environment, the Company’s beliefs, and assumptions made by management. Forward-looking statements include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, its business outlook, growth strategy, financial performance, and other statements that are not historical facts. In some cases, forward-looking statements can be identified by terminology such as “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “potential,” “continues,” or similar expressions. These statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to: the Company’s ability to implement actions necessary to restore compliance with Nasdaq’s listing standards; market volatility affecting the Company’s share price; global and regional economic conditions; competitive pressures; regulatory developments; and the Company’s ability to execute its business strategy and achieve sustainable growth. All information contained in this press release is as of the date hereof, and YY Group Holding Limited undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

About YY Holdings Limited:

YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, technology-enabled platform providing flexible, scalable workforce solutions and integrated facility management (IFM) services across Asia and beyond. The Group operates through two core verticals: on-demand staffing and IFM, delivering agile, reliable support to industries such as hospitality, logistics, retail, and healthcare.

Leveraging proprietary digital platforms and IoT-driven systems, YY Group enables clients to meet fluctuating labor demands and maintain high-performance environments. In addition to its core operations in Singapore and Malaysia, the Group maintains a growing presence in Southeast Asia, Europe, and the Middle East.

Listed on the Nasdaq Capital Market, YY Group is committed to service excellence, operational innovation, and long-term value creation for clients and shareholders.

For more information on the Company, please log on to https://yygroupholding.com/.

Investor Contact
Phua Zhi Yong, Chief Financial Officer
YY Group
Enquiries@yygroupholding.com

Mark Niu, Chief Strategy Officer,
YY Group
mark.niu@yygroupholding.com

• The future-proof 6U MicroBlade delivers cost-effective, green computing solution with integrated Ethernet switches, 96% efficiency Titanium Level power supplies, and unified remote management modules
• Powered by AMD EPYC™ 4005 CPUs, the latest MicroBlade offers 3.3x higher density than traditional 1U servers, up to 160 servers with 2560 CPU cores (per 48U rack)
• Designed for Cloud Computing, Web Hosting, VDI, AI Inference, and Enterprise Workloads, Supermicro’s AMD-based servers enable more server instances per rack

SAN JOSE, Calif., Oct. 24, 2025 /PRNewswire/ — Supermicro, Inc. (NASDAQ: SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, is announcing the latest addition to the AMD based EPYC™ 4005 series CPU Servers, optimized to deliver powerful performance, efficiency, and affordability. Supermicro will feature the new MicroBlade multi-node solution, ideal for companies looking for a scalable and cost-effective solution with centralized management for power, cooling, and networking.

New 6U MicroBlade Systems Powered by AMD EPYC 4005 CPUs

“We continue to expand our portfolio with the new Supermicro MicroBlade, which incorporates AMD EPYC 4005 series processors,” says Charles Liang, president and CEO of Supermicro. “This addition to our successful EPYC-based product line provides a very cost-effective, green computing solution for Cloud Service Providers. A single 48U rack can have up to 160 servers and 16 Ethernet switches, enabling tremendous computing power with built-in switches per enclosure.”

For more information, please visit: https://www.supermicro.com/en/featured/epyc-4000-series

The Supermicro MicroBlade systems powered by AMD EPYC 4005 are built on Supermicro’s unique building block architecture design to deliver unparalleled efficiency, scalability, and affordability. It offers a wide range of benefits to data center customers, including up to 95% cable reduction, 70% space savings, and 30% energy savings over traditional 1U servers. This not only helps enterprises maximize their TCO savings but also opens more opportunities for effectively modernizing their data centers.

The Supermicro MicroBlade contains a dual-port 10GbE network switch, which simplifies network topologies and enables more server instances per rack. The chassis management features include redundant chassis management modules, open industry standard IPMI interfaces, and Redfish APIs, which reduce system management complexity.

Each MicroBlade server blade supports a single AMD EPYC™ 4005 CPU with up to 16 cores, 192GB DDR5 memory, and a dual-slot FHFL GPU. The 6U MicroBlade system can hold up to 20 individual server blades, 2 Ethernet switches, 2 management modules, and offers N+N redundancy providing an ideal and cost-effective solution for dedicated hosting, VDI, online gaming, and AI inferencing.

“We designed the AMD EPYC 4005 Series CPUs with our system partners in mind, creating a processor that enables them to develop differentiated, cost-effective enterprise solutions,” said Derek Dicker, corporate vice president, Enterprise and HPC Business, AMD. “The memory and I/O feature sets, combined with our latest ‘Zen 5’ architecture, give our technology partners the flexibility to create powerful yet affordable systems that meet the specific needs of growing businesses and dedicated hosters.”

The AMD EPYC™ 4005 is at the heart of this innovative solution by offering up to 16 cores and 32 threads on as low as 65W TDP to provide a balance of performance and efficiency at an affordable price. Supermicro MicroBlade TPM 2.0 and AMD Infinity Guard helps datacenters provide another layer of security to protect their data while reducing cost and complexity.

About Super Micro Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first to market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions provider with server, AI, storage, IoT, switch systems, software, and support services. Supermicro’s motherboard, power, and chassis design expertise further enables our development and production, enabling next generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Asia, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions^® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling). 

Supermicro, Server Building Block Solutions, and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

AMD, the AMD logo, EPYC, and combinations thereof are trademarks of Advanced Micro Devices, Inc.

All other brands, names, and trademarks are the property of their respective owners.